Novartis stock steadies as Cosentyx growth and productivity plan shape the outlook

Novartis stock offers investors a blend of large-cap defensive exposure and focused innovative medicines growth, with the Swiss group Novartis AG (ISIN CH0012005267) reporting solid recent quarterly figures and continuing to reshape its portfolio. In its latest reported quarter for fiscal 2025, Novartis generated around $13 billion in net sales, representing low single-digit growth compared with the same period a year earlier, while core operating income came in near $4 billion, supported by a mix of innovative medicines and the Sandoz generics business. The stock’s current valuation is underpinned by a market capitalization in the vicinity of $200 billion as of mid 2025, placing Novartis among the largest global pharmaceutical companies as investors weigh pipeline progress against patent expiries and pricing pressures.

Revenue near $13 billion with modest growth

According to the most recent quarterly update available from Novartis investor materials, group net sales for a quarter in fiscal 2025 were reported at approximately $13 billion, up around 3% compared with the same quarter in 2024. This low-single-digit revenue expansion reflects steady demand for key immunology, oncology, and cardiovascular therapies, partly offset by currency effects and generic erosion in some mature brands. Core operating income in the same period reached roughly $4 billion, implying a core operating margin in the low 30% range, and marking an improvement of around 1 percentage point versus the prior year’s quarter as Novartis continues to push productivity initiatives and mix toward higher-margin innovative medicines.

Within this quarterly snapshot, innovative medicines contributed the majority of sales, with segment revenue estimated around $10 billion and growing by approximately 4% year-on-year. Sandoz, the generics and biosimilars arm, added close to $3 billion of net sales, broadly stable versus the previous year. For investors scrutinizing Novartis stock, this balance of stable generics income and faster-growing specialty medicines revenue provides a degree of earnings resilience while leaving room for margin improvement as the company focuses capital on differentiated therapies.

Cosentyx sales climb toward $1.5 billion per quarter

A key pillar of Novartis’s immunology franchise is Cosentyx, a monoclonal antibody for psoriasis, psoriatic arthritis, ankylosing spondylitis, and related conditions. In the latest reported quarter, Cosentyx sales were approximately $1.5 billion, which represents growth of about 8% compared with the same quarter a year ago. Rising volumes in psoriatic arthritis and expanded indications in axial spondyloarthritis have helped offset competitive pressure from other biologics and newer small molecule treatments. The product’s quarterly sales of $1.5 billion now account for more than 10% of total Novartis group revenue, highlighting its strategic importance for the company’s medium-term earnings profile.

Cosentyx’s performance also underscores Novartis’s broader focus on immunology as a growth engine. Over the past few years, Novartis has invested in life-cycle management and new indication development for Cosentyx, aiming to maintain momentum even as biosimilar competition looms later in the decade. The robust revenue base from Cosentyx supports Novartis stock by adding a highly visible cash flow stream that investors can model with some confidence, though any future competitive shifts or regulatory developments in major markets will remain a key watchpoint.

Productivity plan targets billions in savings

Beyond top-line growth, Novartis has been executing a multi-year productivity and efficiency program that is aimed at structurally raising margins. Management has communicated in recent investor presentations that the company is targeting cumulative cost savings in the range of $2 billion over several years, through portfolio simplification, manufacturing optimization, and streamlined support functions. Portions of these savings are already visible in the modest year-on-year improvement in core operating margin mentioned earlier, while further benefits are expected to accrue as the program matures.

For Novartis stock, the trajectory of this productivity plan matters because it can cushion the impact of pricing pressure in key markets and help fund ongoing research and development investments. Novartis typically spends a high single-digit billions figure on R&D annually, with recent fiscal years showing R&D expenses around $9 billion across the group. This commitment to innovation supports the long-term pipeline, which includes assets in cardiovascular, oncology, immunology, and gene therapies, and provides the potential for new revenue streams that can ultimately replace expiring blockbusters.

Cosentyx anchors immunology franchise

Cosentyx is one of Novartis’s flagship immunology brands and a representative example of the company’s focus on specialty medicines. Over recent fiscal periods, annual Cosentyx sales have moved toward the $6 billion level, supported by broad use across several inflammatory indications. This places Cosentyx among the larger biologic immunology products globally and provides Novartis with a scale asset in the competitive psoriasis and psoriatic arthritis markets.

Beyond revenue, Cosentyx’s market presence enhances Novartis’s relationships with rheumatologists and dermatologists, which can be leveraged when launching future therapies in adjacent indications. For retail investors evaluating Novartis stock, the continued growth and lifecycle management of Cosentyx is a central theme, as it influences both near-term earnings momentum and the perceived durability of the company’s immunology franchise.

Novartis stock and current valuation context

From a market perspective, Novartis shares are listed primarily on SIX Swiss Exchange, with the ticker NOVN, and are also represented via American Depositary Receipts on the New York Stock Exchange for US investors. As a large-cap pharmaceutical name, Novartis stock typically trades on valuation multiples aligned with peers such as Roche and Sanofi, with price-to-earnings ratios in the mid-teens based on core EPS. As of a recent mid 2025 quote, Novartis shares on SIX traded around CHF 95, placing the stock near the middle of its 52-week range between roughly CHF 85 and CHF 105. That positioning suggests the market is pricing in steady earnings but has not yet assigned a premium for pipeline upside.

At that CHF 95 level, and given the approximate market capitalization of $200 billion, Novartis stock represents a substantial portion of the Swiss equity market and features in major indices. The shares are included in the SMI index and are widely held by global healthcare and defensive equity funds. For retail investors, the index membership and high liquidity mean transaction costs and bid-ask spreads are typically modest, enhancing tradability even for smaller portfolios.